Genotypes, phenotypes and treatment with immunomodulators in the rheumatic diseases. (2nd July 2018)

• Record Type: Journal Article
• Authors: van Vollenhoven, R. F.
• Is Part Of: Journal of internal medicine. Volume 284:Number 3(2018)
• Page Start: 228
• Page End: 239
• Publication Date: 2018-07-02
• Subjects: biologicals -- genotypes -- phenotypes -- rheumatoid arthritis -- spondyloarthritis -- systemic lupus erythematosus -- treatment; Internal medicine -- Periodicals; Medicine -- Periodicals; 616
• DOI: 10.1111/joim.12800
• Languages: English
• ISSNs: 0954-6820

Abstract

Abstract: The autoimmune rheumatological diseases rheumatoid arthritis (RA), spondyloarthritis (SpA) and systemic lupus erythematosus (SLE) are treated with conventional immunosuppressive agents and with modern biological immunomodulators. The latter group of medications have brought about a major change in our ability to control RA and SpA, with more modest results for SLE. The biologicals are very specific in their mechanisms of action, targeting one specific cytokine or one particular cellular marker. Because of this, their efficacy can readily be linked to a single immunomodulatory mechanism. This observation has fuelled hopes that the efficacy of these agents can be predicted at the individual level based on the patient's genetic predisposition, immunological profile or disease phenotype. Whilst the biologic therapies have improved the prospects for patients with these diseases very significantly, the hope that they could be targeted to the patient in an individualized manner has not completely born fruit. In this review, I will argue that we are witnessing important progress in this field, and that justified hope exists for true advances in precision medicine in the autoimmune diseases in the coming years.